Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. The company announced that it has start its Phase 1b clinical study of Gemini in CKD patients, while also revealing a 1:16 reverse share split that aids the company with its Nasdaq listing.
